CA3018192C - Beta-aminopateamine A derivatives and methods for treating chronic lymphocytic leukemia - Google Patents

Beta-aminopateamine A derivatives and methods for treating chronic lymphocytic leukemia

Info

Publication number
CA3018192C
CA3018192C CA3018192A CA3018192A CA3018192C CA 3018192 C CA3018192 C CA 3018192C CA 3018192 A CA3018192 A CA 3018192A CA 3018192 A CA3018192 A CA 3018192A CA 3018192 C CA3018192 C CA 3018192C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
methyl
racemate
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3018192A
Other languages
English (en)
French (fr)
Other versions
CA3018192A1 (en
Inventor
Daniel Romo
Kenneth Hull
Mingzhao Zhu
Omar Robles
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Publication of CA3018192A1 publication Critical patent/CA3018192A1/en
Application granted granted Critical
Publication of CA3018192C publication Critical patent/CA3018192C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3018192A 2016-03-31 2017-03-31 Beta-aminopateamine A derivatives and methods for treating chronic lymphocytic leukemia Active CA3018192C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662316299P 2016-03-31 2016-03-31
US62/316,299 2016-03-31
PCT/US2017/025448 WO2017173313A1 (en) 2016-03-31 2017-03-31 Beta-amimo pateamine a derivatives and methods for treating chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
CA3018192A1 CA3018192A1 (en) 2017-10-05
CA3018192C true CA3018192C (en) 2025-05-06

Family

ID=59965302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3018192A Active CA3018192C (en) 2016-03-31 2017-03-31 Beta-aminopateamine A derivatives and methods for treating chronic lymphocytic leukemia

Country Status (7)

Country Link
US (1) US10889596B2 (https=)
EP (1) EP3436007B1 (https=)
JP (1) JP6993348B2 (https=)
CA (1) CA3018192C (https=)
DK (1) DK3436007T3 (https=)
ES (1) ES2913210T3 (https=)
WO (1) WO2017173313A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254195A1 (en) * 2023-06-06 2024-12-12 Baylor University Methods for treating pancreatic cancer with a combination of des-methyl pateamine a and a class 1 hdac inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0647645A1 (en) 1993-10-12 1995-04-12 Pharma Mar, S.A. Novel antitumoral and antiviral compound
US7737134B2 (en) 2002-03-13 2010-06-15 The Texas A & M University System Anticancer agents and use
US7230021B2 (en) 2002-03-13 2007-06-12 The Texas A&M University System Potent, simplified derivatives of pateamine A
US20130053994A1 (en) * 2011-08-31 2013-02-28 General Electric Company Method and apparatus for monitoring radiopharmaceutical processing
WO2013152299A2 (en) * 2012-04-06 2013-10-10 University Of North Carolina At Chapel Hill Inhibitors of eif4a and derivatives of pateamine a with antiviral activity and use

Also Published As

Publication number Publication date
WO2017173313A1 (en) 2017-10-05
EP3436007A1 (en) 2019-02-06
EP3436007A4 (en) 2019-10-09
EP3436007B1 (en) 2022-03-02
DK3436007T3 (da) 2022-03-14
US10889596B2 (en) 2021-01-12
JP2019510070A (ja) 2019-04-11
CA3018192A1 (en) 2017-10-05
JP6993348B2 (ja) 2022-02-15
US20190177339A1 (en) 2019-06-13
ES2913210T3 (es) 2022-06-01

Similar Documents

Publication Publication Date Title
JP7365059B2 (ja) 縮合チオフェン化合物
AU2017281903B2 (en) Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
US20220169628A1 (en) Therapeutic agents and methods of treatment
US11065226B2 (en) Combination comprising EP4 antagonist and immune checkpoint inhibitor
CA3224492A1 (en) Immunoconjugates and methods
IL267031A (en) Selectively converted quinoline compounds
TW201720816A (zh) Ｃｘｃｒ２抑制劑
JP2019521082A (ja) Ｌｓｄ１／ｈｄａｃ二重阻害剤としてのシクロプロピル−アミド化合物
JP6918378B2 (ja) ＣａＭＫＩＩ阻害剤及びその使用
JP2020527577A (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
TW201728579A (zh) 作為檢測點激酶1 (chk1)抑制劑之3,5-二取代吡唑及其製備及應用
IL288508B2 (en) History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
EP4527415A1 (en) Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
JP2022521605A (ja) 統合的ストレス応答経路の阻害剤
CA3119957A1 (en) Novel imidazole derivative
TW201030011A (en) Imidazothiazole derivatives bearing the proline ring structure
US10870662B2 (en) Alpha-amino pateamine A derivatives and methods for treating chronic lymphocytic leukemia
AU2009284086B2 (en) New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents
CA3018192C (en) Beta-aminopateamine A derivatives and methods for treating chronic lymphocytic leukemia
JP2022522890A (ja) 芳香族誘導体、その調製方法および医薬用途
US10676504B2 (en) Method for preparing largazole analogs and uses thereof
WO2025067394A1 (zh) 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用
US20250059213A1 (en) Lonp1 inhibitors, uses and methods
US20250026747A1 (en) Colibactin derivatives and methods of treating, ameliorating, and/or preventing cancer
JP2024540428A (ja) 分解剤及びその使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220113

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250304

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250313

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250313

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250501

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250526

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260217